fig2

Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy

Figure 2. The change in absolute standardized mean difference (ASMD) of the seven clinical characteristics included in the propensity score (PS) in a simulated cohort of 100 tenofovir disoproxil fumarate (TDF)- and 900 entecavir (ETV)-treated simulated patients before and after (A) PS matching and (B) weighting. DM: Diabetes mellitus; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/